Apogenix plans to out-license the worldwide marketing rights for APG101 for the treatment of GBM and aGvHD, plus further potential indications, to partners in the pharmaceutical or biotechnology industry. The IL-4 blockers will be out-licensed upon completion of preclinical development at the earliest. The company seeks to establish close research collaborations with leading academic institutions and other biopharmaceutical companies.